Norlys TV customers will see their monthly bills rise by up to 20 DKK starting July 1st. According to the company, this ...

S&P 500 E-Mini futures are up +0.98%, andJune Nasdaq 100 E-Mini futures are up +1.05% this morning, signaling a rebound from yesterday’s sell-off on Wall Street, while inve ...

Danish Prime Minister Mette Frederiksen and Greenland’s new Premier, Jens-Frederik Nielsen, met Sunday at Marienborg to ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...

Novo Nordisk, the Danish maker of Ozempic and Wegovy ... moving ahead in the race between drugmakers to offer a weight loss pill. The move comes less than a week after Novo’s largest rival ...